Effects of glucose and blood pressure variability on oxidative stress in patients with type 2 diabetes mellitus and hypertension: A cross-sectional study
Not Applicable
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000035615
- Lead Sponsor
- Showa University School of Medicine, Division of Diabetes and Endocrinology, Department of Internal Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)the use of steroids or anti-inflammatory drugs, 2)diabetic ketosis and coma within 3 months before the study, 3)severe infection, severe trauma, pre-and post-operation, 4)an estimated glomerular filtration rate are within 30mL/min/1.73m2, 5)severe liver dysfunction, 6)malignancy, 7)pregnancy, 8)secondary hypertension, 9)Patients who are judged as inappropriate for inclusion by phsicians
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link glucose and blood pressure variability to oxidative stress in type 2 diabetes and hypertension?
How does glucose variability compare to blood pressure variability in predicting oxidative stress markers like 8-OHdG in T2DM patients?
Which biomarkers correlate with oxidative stress response to glucose/BP fluctuations in Showa University's cross-sectional study?
What adverse events are associated with oxidative stress management in patients with T2DM and hypertension using SGLT2 inhibitors or ACE inhibitors?
How do combination therapies targeting both glycemic control and blood pressure stability affect oxidative stress in T2DM and hypertension populations?